CA2756583A1 - Dispositif d'administration de medicaments - Google Patents

Dispositif d'administration de medicaments Download PDF

Info

Publication number: CA2756583A1
Authority: CA; Canada
Prior art keywords: piston rod; nut; drug delivery; delivery device; reset
Prior art date: 2010-03-31
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA2756583A

Other languages

English (en)

Inventor

Michael Harms

Volker Korger

Uwe Dasbach

Steffen Raab

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Sanofi Aventis Deutschland GmbH

Original Assignee

Sanofi Aventis Deutschland GmbH

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-03-31

Filing date

2010-03-31

Publication date

2010-10-14

2010-03-31 Application filed by Sanofi Aventis Deutschland GmbH filed Critical Sanofi Aventis Deutschland GmbH

2010-03-31 Priority claimed from PCT/EP2010/054343 external-priority patent/WO2010115818A1/fr

2010-10-14 Publication of CA2756583A1 publication Critical patent/CA2756583A1/fr

Status Abandoned legal-status Critical Current

Links

238000012377 drug delivery Methods 0.000 title claims description 38
230000033001 locomotion Effects 0.000 claims abstract description 46
230000007246 mechanism Effects 0.000 claims abstract description 35
229940079593 drug Drugs 0.000 claims abstract description 29
239000003814 drug Substances 0.000 claims abstract description 29
239000000463 material Substances 0.000 claims description 13
230000002401 inhibitory effect Effects 0.000 claims description 2
JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 50
108010011459 Exenatide Proteins 0.000 description 47
229960001519 exenatide Drugs 0.000 description 47
101000976075 Homo sapiens Insulin Proteins 0.000 description 22
QEFRNWWLZKMPFJ-YGVKFDHGSA-N L-methionine S-oxide Chemical compound CS(=O)CC[C@H](N)C(O)=O QEFRNWWLZKMPFJ-YGVKFDHGSA-N 0.000 description 22
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 21
239000011295 pitch Substances 0.000 description 16
230000008878 coupling Effects 0.000 description 10
238000010168 coupling process Methods 0.000 description 10
238000005859 coupling reaction Methods 0.000 description 10
238000002347 injection Methods 0.000 description 10
239000007924 injection Substances 0.000 description 10
150000003839 salts Chemical class 0.000 description 8
150000001875 compounds Chemical class 0.000 description 7
230000004888 barrier function Effects 0.000 description 6
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 5
206010012601 diabetes mellitus Diseases 0.000 description 4
239000012530 fluid Substances 0.000 description 4
229940127215 low-molecular weight heparin Drugs 0.000 description 4
108090000765 processed proteins & peptides Proteins 0.000 description 4
150000004676 glycans Chemical class 0.000 description 3
229940088597 hormone Drugs 0.000 description 3
239000005556 hormone Substances 0.000 description 3
239000003055 low molecular weight heparin Substances 0.000 description 3
229920001282 polysaccharide Polymers 0.000 description 3
239000005017 polysaccharide Substances 0.000 description 3
208000004476 Acute Coronary Syndrome Diseases 0.000 description 2
208000002249 Diabetes Complications Diseases 0.000 description 2
206010012689 Diabetic retinopathy Diseases 0.000 description 2
108010088406 Glucagon-Like Peptides Proteins 0.000 description 2
108090001061 Insulin Proteins 0.000 description 2
102000004877 Insulin Human genes 0.000 description 2
239000002253 acid Substances 0.000 description 2
150000001447 alkali salts Chemical class 0.000 description 2
238000006073 displacement reaction Methods 0.000 description 2
230000002349 favourable effect Effects 0.000 description 2
229940125396 insulin Drugs 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
238000011321 prophylaxis Methods 0.000 description 2
239000012453 solvate Substances 0.000 description 2
238000011282 treatment Methods 0.000 description 2
238000004804 winding Methods 0.000 description 2
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
125000001831 (C6-C10) heteroaryl group Chemical group 0.000 description 1
208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
206010002383 Angina Pectoris Diseases 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
108010037003 Buserelin Proteins 0.000 description 1
125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
125000000041 C6-C10 aryl group Chemical group 0.000 description 1
108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 1
208000005189 Embolism Diseases 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
102400000932 Gonadoliberin-1 Human genes 0.000 description 1
108010069236 Goserelin Proteins 0.000 description 1
BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
101500026183 Homo sapiens Gonadoliberin-1 Proteins 0.000 description 1
239000000854 Human Growth Hormone Substances 0.000 description 1
102000002265 Human Growth Hormone Human genes 0.000 description 1
108010000521 Human Growth Hormone Proteins 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
108010000817 Leuprolide Proteins 0.000 description 1
229920000106 Liquid crystal polymer Polymers 0.000 description 1
102000009151 Luteinizing Hormone Human genes 0.000 description 1
108010073521 Luteinizing Hormone Proteins 0.000 description 1
108010021717 Nafarelin Proteins 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
101000579646 Penaeus vannamei Penaeidin-1 Proteins 0.000 description 1
101000579647 Penaeus vannamei Penaeidin-2a Proteins 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
208000010378 Pulmonary Embolism Diseases 0.000 description 1
108010010056 Terlipressin Proteins 0.000 description 1
208000001435 Thromboembolism Diseases 0.000 description 1
108010050144 Triptorelin Pamoate Proteins 0.000 description 1
239000003513 alkali Substances 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
229960002719 buserelin Drugs 0.000 description 1
CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
230000002301 combined effect Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
229960004281 desmopressin Drugs 0.000 description 1
NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
229960005153 enoxaparin sodium Drugs 0.000 description 1
229960001442 gonadorelin Drugs 0.000 description 1
XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
229960002913 goserelin Drugs 0.000 description 1
239000000122 growth hormone Substances 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
229920002674 hyaluronan Polymers 0.000 description 1
229960003160 hyaluronic acid Drugs 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
239000000960 hypophysis hormone Substances 0.000 description 1
210000003016 hypothalamus Anatomy 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
239000004026 insulin derivative Substances 0.000 description 1
GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
229960004338 leuprorelin Drugs 0.000 description 1
208000002780 macular degeneration Diseases 0.000 description 1
229940126601 medicinal product Drugs 0.000 description 1
239000000203 mixture Substances 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
RWHUEXWOYVBUCI-ITQXDASVSA-N nafarelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 RWHUEXWOYVBUCI-ITQXDASVSA-N 0.000 description 1
229960002333 nafarelin Drugs 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
-1 polyoxymethylene Polymers 0.000 description 1
229920006324 polyoxymethylene Polymers 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000000979 retarding effect Effects 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
229960004532 somatropin Drugs 0.000 description 1
239000000126 substance Substances 0.000 description 1
229920002994 synthetic fiber Polymers 0.000 description 1
229960003813 terlipressin Drugs 0.000 description 1
BENFXAYNYRLAIU-QSVFAHTRSA-N terlipressin Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CN)CSSC1 BENFXAYNYRLAIU-QSVFAHTRSA-N 0.000 description 1
CIJQTPFWFXOSEO-NDMITSJXSA-J tetrasodium;(2r,3r,4s)-2-[(2r,3s,4r,5r,6s)-5-acetamido-6-[(1r,2r,3r,4r)-4-[(2r,3s,4r,5r,6r)-5-acetamido-6-[(4r,5r,6r)-2-carboxylato-4,5-dihydroxy-6-[[(1r,3r,4r,5r)-3-hydroxy-4-(sulfonatoamino)-6,8-dioxabicyclo[3.2.1]octan-2-yl]oxy]oxan-3-yl]oxy-2-(hydroxy Chemical compound [Na+].[Na+].[Na+].[Na+].O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1O)NC(C)=O)O[C@@H]1C(C[C@H]([C@@H]([C@H]1O)O)O[C@@H]1[C@@H](CO)O[C@H](OC2C(O[C@@H](OC3[C@@H]([C@@H](NS([O-])(=O)=O)[C@@H]4OC[C@H]3O4)O)[C@H](O)[C@H]2O)C([O-])=O)[C@H](NC(C)=O)[C@H]1C)C([O-])=O)[C@@H]1OC(C([O-])=O)=C[C@H](O)[C@H]1O CIJQTPFWFXOSEO-NDMITSJXSA-J 0.000 description 1
229960004824 triptorelin Drugs 0.000 description 1
VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
210000003462 vein Anatomy 0.000 description 1

Landscapes

Infusion, Injection, And Reservoir Apparatuses (AREA)

CA2756583A 2010-03-31 2010-03-31 Dispositif d'administration de medicaments Abandoned CA2756583A1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/EP2010/054343 WO2010115818A1 (fr)	2009-03-31	2010-03-31	Dispositif d'administration de medicaments

Publications (1)

Publication Number	Publication Date
CA2756583A1 true CA2756583A1 (fr)	2010-10-14

Family

ID=46232415

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2756583A Abandoned CA2756583A1 (fr)	2010-03-31	2010-03-31	Dispositif d'administration de medicaments

Country Status (1)

Country	Link
CA (1)	CA2756583A1 (fr)

2010
- 2010-03-31 CA CA2756583A patent/CA2756583A1/fr not_active Abandoned

Publication	Publication Date	Title
US10398845B2 (en)	2019-09-03	Drug delivery device
EP2414007B1 (fr)	2015-03-04	Dispositif d'administration de médicaments
EP2482892B1 (fr)	2013-08-28	Mecanisme d'entrainement pour dispositif d'approvisionnement de medicament
US8939945B2 (en)	2015-01-27	Drive mechanism for a drug delivery device
EP2475410B1 (fr)	2020-04-15	Mécanisme de commande pour dispositif d'administration de médicaments et dispositif d'administration de médicaments
CA2756583A1 (fr)	2010-10-14	Dispositif d'administration de medicaments
HK1166729B (en)	2020-04-17	Drug delivery device
HK1166729A (en)	2012-11-09	Drug delivery device
HK1166728B (en)	2015-08-21	Drug delivery device
HK1169054B (en)	2014-11-07	Drive mechanism for a drug delivery device
HK1168821B (en)	2014-04-04	Drive mechanism for a drug delivery device

Legal Events

Date	Code	Title	Description
2015-04-14	EEER	Examination request	Effective date: 20150327
2018-05-15	FZDE	Discontinued	Effective date: 20180403